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Abbreviation key 35 
ATRT Atypical teratoid rhabdoid tumor 
CNS Central nervous system 
DIPG Diffuse intrinsic pons glioma  
EPN Ependymoma 
FA Fractional anisotropy 
FLAIR Fluid attenuation inversion recovery 
GBM Glioblastoma multiforme 
GTR Gross total resection 
HGG High-grade glioma 
IVM Intracerebral vascular malformations 
LGG Low-grade glioma 
MB Medulloblastoma 
MRI Magnetic resonance imaging 
PBL Pineoblastoma 
PNET Primitive neuroectodermal tumor   
SMN Secondary malignant neoplasm 
stPNET Supratentorial primitive neuroectodermal 
tumor  
WML White matter lesion 
 36 
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 Abstract  38 
Brain tumors are the second most common childhood cancer. Treatment protocols for high-grade 39 
pediatric brain tumors recommend regular follow-up imaging for up to ten years. We review 40 
maximal time to recurrence and minimal time to radiologically detectable long-term sequelae 41 
like secondary malignancies, vascular complications and white matter disease. No tumors 42 
recurred after the ten-year point, but radiological long-term sequelae grew more common as the 43 
treatment completion date receded. We do not recommend regular imaging more than ten years 44 
after treatment has ended, unless there are clinical symptoms.  45 
 46 
  47 
 48 
 49 
 50 
 51 
 52 
 53 
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Introduction  56 
Tumors of the central nervous system (CNS) are the second most common tumor in childhood 57 
after leukemia. The incidence is comparable in western countries (5.47/100,000 aged 0-14 years 58 
and 5.67/100,000 aged 0-19 years in the US, 2-4/100,000 aged 0-15 years in Germany and 59 
Switzerland)1,2. Advances in imaging techniques, neurosurgery, radiotherapy, chemotherapy and 60 
supportive care have increased the survival rate significantly. Five-year relative survival for all 61 
brain tumors has increased from around 60% at the end of the 1970s to around 72.5% by 2007-62 
20133, though the survival rate varies between different pediatric CNS tumors. When they are 63 
cured of their primary malignancy, children need regular follow-up investigations and screenings 64 
for tumor recurrence and long-term side effects caused by chemotherapy, radiotherapy, surgery 65 
or the tumor itself. For most tumors, a national and/or international treatment protocol 66 
recommends procedures for initial diagnosis, treatment and follow up, but these 67 
recommendations usually cover only the first five or ten years after the end of treatment.  68 
 69 
This review summarizes the most important findings detectable on imaging ten years or more 70 
after the end of treatment for pediatric high-grade brain tumors, which includes the period of 71 
possible tumor recurrence. We also summarize possible long-term sequelae visible on imaging 72 
(secondary malignant neoplasm, vascular complications, and white matter disease) caused by the 73 
treatment.  74 
 75 
Methods 76 
We used PubMed for the literature search. Search terms included the different biological types of 77 
high-grade brain tumors (medulloblastoma [MB], ependymoma [EPN], supratentorial primitive 78 
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neuroectodermal tumor [stPNET], atypical teratoid rhabdoid tumor [ATRT], malignant 79 
glioma/high grade glioma [HGG] and diffuse intrinsic pons glioma [DIPG]) and the term 80 
“embryonal tumors”. In addition to the single biological subtypes we  combined those with the 81 
terms “surveillance imaging”, “relapse”, “relapse pattern”, “outcome”, “cavernoma”, 82 
“intracerebral cavernous malformations”, “intracerebral vascular malformations” (IVM), 83 
“secondary malignant neoplasm (SMN)”, “secondary malignancy”, ”leukomalacia”, 84 
“leukoencephalopathy”, “white matter” and “childhood”. We also screened the reference lists of 85 
the eligible publications.  86 
Inclusion criteria for all publications are diagnosis of a high-grade brain tumor and age at first 87 
tumor diagnosis of 0-18 years. We also included publications with patient aged >18 years if the 88 
proportion of the pediatric population was described separately. An additional inclusion criterion 89 
for tumor recurrence was diagnosis after 1999; these studies have comparable and less 90 
heterogeneous treatment modalities, especially for radiotherapy. We only evaluated time to first 91 
recurrence. Secondary malignant neoplasm, intracerebral vascular malformation, and 92 
leukoencephalopathy have separate inclusion criteria for the year of first tumor diagnosis (after 93 
1989) and year of publication (after 1999).  94 
We excluded all publications with less than 10 patients and those where leukoencephalopathy 95 
developed during the treatment. Patients with tumor predisposition syndrome are excluded, as in 96 
this population follow-up recommendations are more complex and have to include multiple 97 
different tumor types also outside of the CNS.  98 
 99 
Results 100 
Tumor recurrence 101 
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Table 1 provides an overview of the most important findings from the eligible studies on tumor 102 
recurrence. 103 
 104 
Medulloblastoma (MB) 105 
Medulloblastoma make up 15-30% of all brain tumors and are the second most common brain 106 
tumor after astrocytoma4. Around 50% develop before the age of 5 years. Initial metastatic 107 
disease is present in about one third5,6.  108 
Tumor recurrence rate was between 18.7%-40%. 5,7-14. No relapse occurred more than ten years 109 
after diagnosis. The longest documented latency period was 7.9 years, in a patient with standard 110 
risk MB7. The proportion of late relapse, arbitrarily defined as >5 years from diagnosis, is 111 
mentioned in two publications and is 8% and 7% respectively7,8. According to Sabel et al. and 112 
Perreault et al. 69% and 46% of all recurrences were asymptomatic and detected by surveillance 113 
MRI7,9,10.  114 
 115 
Ependymoma (EPN) 116 
EPN represent 10 % of all CNS tumors in childhood. They occur mostly in the first decade of 117 
life and more than 50% of children are aged <5 years at diagnosis. EPN present with initial 118 
leptomeningeal dissemination in 5-10% of cases4,15,16. 119 
30 – 54% of patients relapsed between 1 month and 8.6 years from diagnosis, with am mean of 120 
12 to 19 month9,17-20. No data concerning symptomatic or asymptomatic recurrence are available. 121 
 122 
Atypical teratoid rhabdoid tumor (ATRT)  123 
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ATRT are rare (1-2%) brain tumor in childhood and affect predominantly infants and toddlers. 124 
About two-third of newly diagnosed ATRT occur before the age of 3 years. In 21-30%, 125 
dissemination is present at initial diagnosis21-23.  126 
Relapse occur in 40 – 74% of patients with a mean latency period around 5 month and the latest 127 
relapse after 3.2 years9,24-28. No data concerning symptomatic or asymptomatic recurrence are 128 
available.  129 
 130 
Central nervous system primitive neuroectodermal tumors (CNS-PNET), Pineoblastoma (PBL) 131 
CNS-PNET and PBL represent 2.5% - 4.8% and 0.6% of all CNS tumors respectively4,29. In the 132 
reviewed literature, initial metastatic disease was present 35% and 48% respectively 10,30.  133 
The rate of recurrence was between 42% and 76%10,30,31. The latest manifestation occurred after 134 
4.5 years in a patient with CNS-PNET10. No data concerning symptomatic or asymptomatic 135 
recurrence available.  136 
 137 
High-grade glioma (HGG) and Diffuse intrinsic pons glioma (DIPG)  138 
HGG together with DIPG represent 8 - 17% of all CNS tumors in childhood and adolescence up 139 
to 19 years of age and are responsible for a relevant part of mortality (up to 40% of all brain 140 
tumors)4,32,33. According to data from four consecutive German HGG protocols, about 3% have 141 
initial metastatic disease34.  142 
The rate of progressive disease after one year was 75% in the study from Macy et al35. The event 143 
free-survival after one year was higher (43%) according to Wolff et al36. The 5-year event-free 144 
survival in this cohort was 13%.  145 
 146 
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Radiological long-term sequelae  147 
Table 2 summarizes the most important findings from the eligible studies on SMN, IVM and 148 
WML. 149 
 150 
Secondary malignant neoplasia  151 
The median follow-up from diagnosis for the six eligible studies ranges from 1.0 to 10.0 years 152 
with a maximum of 15.0 years7,11,37-40. The primary diagnosis was either medulloblastoma, 153 
ependymoma or HGG/DIPG. All SMN occurred in patients after radiotherapy. Secondary brain 154 
tumors were detected in 0.1 – 4.1% of former brain tumor patients. The histology of all 19 155 
cerebral SMN are available7,11,37-40. Hereof 79% are high-grade lesions (high-grade glioma and 156 
PNET), 15% are meningioma, and 5% are pilocytic astrocytoma. Time to detection of SMN is 157 
available from five studies, ranging from 2.4 years (PNET) to 10.3 years (high-grade 158 
glioma)7,11,37-39. Time to detection of low-grade tumors is available in two cases and is 6.5 years 159 
(pilocytic astrocytoma) and 10.2 years (meningioma) respectively37,39. In case of high-grade 160 
tumors (n=11) time ranges from 2.4 to 10.3 years.  161 
 162 
Intracerebral vascular malformations  163 
Only one study assessing radiation-induced cavernoma in medulloblastoma patients fulfilled the 164 
inclusion criteria41. During the observation period of mean 7.2 years, 31% developed at least one 165 
intracerebral cavernoma. The cumulative incidence rate was 5.6%, 14% and 43% 3, 5 and 10 166 
years following radiotherapy for MB. Time to detection of a vascular malformation lied between 167 
1.1 and 16.1 years with a median of 6.6 years. One out of 18 patients had clinical symptoms at 168 
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diagnosis. He presented five years after treatment with seizure, headache, and emesis. All 169 
patients received radiotherapy to the brain.  170 
 171 
Leukoencephalopathy/ White matter lesions  172 
WML is a well-known late effect after treatment for pediatric brain tumors, either after focal 173 
irradiation or after low dose craniospinal radiotherapy and chemotherapy42,43. Depending on the 174 
severity, mostly studies classify WML in grade 1-3, rarely up to grade 4. Grade 1 lesions 175 
correspond to small areas with high signal in T2* and FLAIR in MRI. These lesions increase in 176 
grade 2 and become cystic or hemorrhagic in grade 3 and 4 lesions44. These changes can occur in 177 
parallel with an increase in subarachnoidal space and ventriculomegaly43.  Different grades of 178 
WML can manifest in the same patient42-45. The incidence of WML lies between 33% and 179 
100%42-46. Two studies included MB only42,45,46; the remaining two include more than one 180 
biological type of brain tumor43,44. All patients received different combinations of chemotherapy 181 
and radiotherapy. The percentage of grade 1 lesions in each study ranges from 33 to 66%. Grade 182 
II lesions and grade III lesions were visible in 7-33% and 29% respectively.  183 
 184 
Discussion  185 
We found no recurrence of the primary brain tumor, either local or distant, ten years or more 186 
after the end of treatment in the reviewed literature5,7-14,18-20,24-28,30,31,35,36,47,48. After combining 187 
the latency period from all relapses, median time to relapse was 13.7 months; average minimal 188 
latency times were 3.3 months and a maximum of 49.0 months. A patient diagnosed with 189 
ependymoma had the longest latency period (103 months). Overall, these results do not seem to 190 
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justify routine screening to detect tumor recurrence more than ten years after the end of 191 
treatment. 192 
 193 
Radiotherapy is a known risk factor for developing SMN in the previously irradiated field. Data 194 
from the large Childhood Cancer Survivor Study (CCSS) show that the risk for SMN in the brain 195 
increases as the diagnosis recedes. Results from large studies emphasise a linear dose-response-196 
relationship between meningioma and glioma as SMN with a steady increase of occurrence for 197 
both tumors over time (cumulative incidence 3.3% at 25 years; 3.5% at 30 years)49,50. Most of 198 
the SMN in the reviewed literature are high-grade tumors. Only two studies reported occurrence 199 
of secondary meningioma37,40. Studies with longer follow-up periods show a larger proportion of 200 
secondary meningioma. In the CCSS cohort, the cumulative incidence of benign meningioma 201 
was 3.3% after a median follow-up of 19.6 years51. The latency period for SMN in the brain is 202 
very heterogeneous in the reviewed literature (2.4 to 10.3 years) and the development of SMN 203 
follows no predictable pattern. For slowly growing tumors (e.g. meningioma), the prognosis is 204 
not inferior if the tumor is diagnosed due to clinical symptoms compared to earlier detection by 205 
surveillance MRI. Data of women with newly diagnosed meningioma during pregnancy support 206 
this suggestion52-54. In case of absent neurological symptoms or deterioration, the management 207 
provides tight follow-up and surgery after delivery. The interval between diagnosis and surgery 208 
can thereby last up to several weeks52-54. To detect fast-growing secondary brain tumors (e.g. 209 
GBM) in an early stage, the interval between the scans would have to be very short. Even though 210 
the possibility is high to miss the tumor on MRI because the tumor was not visible on the 211 
previous but manifests clinically before the subsequent examination. In summary, it is not 212 
possible to recommend regular screening for early detection of SMN. 213 
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 214 
Cavernoma occur more often in previously irradiated patients and detection rate depends on 215 
imaging techniques. The prevalence of cavernoma in the reviewed study is 31%. This prevalence 216 
is higher than in non-irradiated children and young adults with a prevalence of 0.6%55 and also 217 
higher than in other publications including patients partially diagnosed before 1990 with rates of 218 
3.4% and 4.2%56,57. Different MRI techniques could cause some of these differences. In the 219 
study from Burn et al. no T2*-weighted  imaging was performed56. This technique is sensitive to 220 
detect blood artefacts and was used in the reviewed study. Studies including patients from past 221 
eras, not using specific MR techniques, probably underestimate the prevalence of cavernoma. 222 
Cavernoma bear the risk of spontaneous bleeding. In the study from Lew et al. 20 lesions were 223 
longitudinally followed41. They increased in size in 70% of cases, were stable in 15%, and a 224 
decreased in 15%. Despite an increase in size in 70% of cases, no patient suffered from acute 225 
bleeding during the follow-up period. The hemorrhage rate in non-irradiated children is 3.3% 226 
and 1.6% per patient-year respectively55,58. Other publications show a bleeding rate for radiation-227 
induced cavernoma of 10%59. Radiation dose and time of follow-up may have an effect on the 228 
development of cavernoma. Unfortunately, the reviewed study did not comment on the possible 229 
effect of radiation dose. Cutsforth et al. showed, that patients treated with higher radiation doses 230 
had a shorter period to detection of cavernoma59. Burn et al. showed no correlation between 231 
radiation dose and the latency period56.  According to Lew et al. with increasing time from end 232 
of treatment, the cumulative incidence of cavernoma increases41. With the knowledge of the 233 
dynamic behaviour in the natural course of cavernoma, we recommend a wait-and-see strategy 234 
with close follow-up imaging in case of an asymptomatic incidental finding. Due to the wide 235 
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range of latency period to detection of cavernoma, no interval for regular follow-up imaging can 236 
be deduced.  237 
A second cerebral vascular disorder observed after radiotherapy to the brain is moyamoya. Most 238 
studies evaluating moyamoya after radiotherapy include to a large proportion patients with 239 
neurofibromatosis 1 (NF1), a tumor predisposition syndrome. These patients are at increased risk 240 
for moyamoya independent of radiotherapy and separate guidelines for surveillance imaging 241 
exist. After excluding these patients from otherwise eligible studies, the number of patients 242 
without moyamoya is far less than 1060,61. Both studies showed that radiation to the circle of 243 
Willisi or the supratentorial region is a risk factor for moyamoya. In the study from Ullrich et al., 244 
the high rate of optic pathway glioma and therefore patients with probably having NF1 might 245 
bias this observation. In the population of Wu et al., only 25% suffered from optic pathway 246 
glioma, but all received suprasellar radiotherapy. Therefore, suprasellar radiotherapy seems to be 247 
a risk factor for moyamoya. 248 
 249 
Most WML in the reviewed literature are grade 1. In the cohort from Dietrich et al., no child 250 
with WML suffered from neurological deficits, but specific neuropsychological testing was not 251 
performed. In three studies, imaging by conventional MRI was completed by the measurement of 252 
white matter anisotropy, performed by fractional anisotropy (FA) 42,45,46. Results show a relevant 253 
reduction of FA in selected parts of the brain in previously irradiated children compared to non-254 
irradiated brains. There seems to be a correlation between FA-reduction and younger age at 255 
radiotherapy as well as a time span of more than 5 years after radiation. A reduced FA or white 256 
matter integrity shows a correlation with lower cognitive outcome and executive functions42,46. It 257 
seems that special imaging modalities (e.g. diffusion weighted imaging, measurement of 258 
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anisotropy) are more sensitive in detection of white matter lesions than T2 weighted images 259 
alone42. The consequences of detected WML of any grade and the implications for therapeutic 260 
interventions are the focus of current research. We assume that early intervention, already 261 
preventive, with specific neuropsychological training help these patients to prevent the 262 
development or progression of impaired cognitive and executive functions. 263 
 264 
The small number of studies that were eligible after we applied strict inclusion criteria, 265 
especially the limits imposed by year of diagnosis and the requirement for at least 10 patients 266 
limited our review. Since diagnoses were 1990 and onwards, the follow-up period was short, 267 
which probably biases the distribution towards more high-grade SMN and underestimates the 268 
rate of low-grade SMN. The large differences in cumulative incidence rate of vascular 269 
malformations we identified is most likely a result of small sample sizes and imaging techniques. 270 
Patients have been treated with newer modalities, so our results apply to survivors now entering 271 
follow-up care.   272 
   273 
If a patient has strong new headache or neurological symptoms 10 years or more after treatment 274 
for a high-grade brain tumor, we recommend prompt imaging, including appropriate sequences 275 
for vascular diseases. If imaging reveals a cavernoma in a critical region, we recommend regular 276 
follow-up imaging 62. We do not recommend surveillance imaging for small cavernoma in non-277 
critical regions41.  278 
We found that screening imaging more than 10 years after completing treatment for childhood 279 
high-grade brain tumors is not indicated in absence of clinical symptoms because tumors do not 280 
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recur after such a long period of time, and long-term sequelae (SMN, IVM, WML) occur in such 281 
a broad time spectrum that no reasonable interval for screening imaging can be defined. 282 
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TABLE 1 Overview of the most important findings from the eligible studies on tumor recurrence  
Study/ Year Trial type 
Year of diagnosis 
FU, y, median  
Number of 
patients 
Number of 
relapse % (n) 
Latency from primary 
diagnosis to relapse, mo, 
median 
Medulloblastoma 
Dufour et al, 201411 Single center, prospective 
2001 - 2010 
FU: 0.8 – 11.3 (4.4) 
21 28.5% (6) 9.2 – 74.4 (19.5) 
 
Koschmann et al, 20168 Single center, retrospective 
2000 - 2010 
FU: 3.6 – 62.6 (18.0) 
47  
 
29.8 % (14) 3.6 – 62.6 (18.0) 
Odagiri et al, 201412 Single center, retrospective 
2003 - 2011 
FU: 1.9 – 9.1 (6.5) 
16 18.7% (3) n.a.  
Perreault et al, 2013 and 
20149,10 
Two centers, retrospective 
2000 – 2011 
FU: 0.23 – 11.8 (4.3) 
89 29.2% (26) 0.5 – 76 (16) 
Sabel et al, 20167 Multicenter, prospective 
2001 - 2006 
FU: (7.8) 
338 21% (72) 
 
2 - 95 (26) 
Sung et al, 201313 Single center, prospective 
2005 - 2010 
FU: 1.9 – 6.8 (3.8) 
20 20% (4) 6 – 21  
Von Bueren at al, 20115 Multicenter, prospective 
2001 - 2005 
FU: 1.3 – 8.2 (4.5) 
45 40% (18) 2.4 – 53.9 (15.6) 
Von Bueren et al, 201614 Multicenter, prospective  
2001 – 2007 
FU: 1.2 – 9.5 (5.4) 
123 38.2% (47) SHH group: 9.6 – 16.8 (12.8) 
Group 3: 1.2 – 38.4 (9.6) 
Group 4: 4.8 – 92.4 (32.4) 
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Ependymoma 
Massimio et al, 201618 Multicenter, prospective 
2002 - 2014 
FU: 3.4 – 9.1 (5.6) 
160 30.6% (49) 4 – 103 (19) 
Perreault et al, 20149 Two centers, retrospective 
2000 – 2011 
FU: 0.5 – 11.1 (3.9) 
52  50% (26) 1 – 65 (16) 
Rootman et al, 201747 Single center, retrospective  
2000 - 2015 
FU: n.a. 
35 54% (19) 3 – 30 (18) 
Sato et al, 201719 Retrospective  
2000 - 2013 
FU IMRT group: 1.1 – 11.7 (4.9) 
FU PRT group: 0.6 – 7.2 (2.6) 
79 35.4% (28) 
 
no recurrence after 5 years 
Tensaouti et al, 201720 Multicenter, retrospective 
2000 - 2013 
FU: (4.5) 
202 41.6% (84) n.a.  
Venkatramani et al, 201348 Prospective, multicenter 
2004 - 2009 
FU: (3.5) 
19 47% (9) 4 – 31 (12) 
Atypical teratoid rhabdoid tumor  
Bartelheim at al, 201624 Multicenter, prospective 
2005 - 2009 
FU: 5 – 8 (6.4) 
31 52% (15)  
 
 
1 – 37 (6.5) 
Benesch et al, 201425 Multicenter, retrospective 
2005 - 2011 
FU : 0.6 – 6.9 (1.3)  
19 74% (14) (14) 
Chi et al, 200926 Multicenter, prospective  
2004 – 2006  
FU: up to 2.9 
20 40% (8) 1.2 – 26 (5.4) 
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Perreault et al, 2013 and 
20149,10 
Two centers, retrospective 
2000 – 2011 
FU: 0.16 – 5.4 (0.5) 
10 40% (4) 2.75 – 9 (5.5) 
Sung et al, 201627 Prospective 
2004 – 2012 
FU: 3.2 – 9 (5.3)  
13 69% (9) 
 
 
1 – 73 (5) 
Zaky et al, 201428 Prospective, multicenter  
2003 – 2009 
FU: n.a. 
19 73% (11)  
 
0.8 – 39.3 (4.1) 
Central nervous system primitive neuroectodermal tumors (CNS-PNET), Pineoblastoma (PBL) 
Friedrich et al, 201330 Multicenter, prospective  
2001 - 2005 
FU: 2.1 – 9.6. (8.3)  
17 
CNS-PNET 
and PBL 
76% (13) 2.3 – 8.8 (5.0) 
Gerber at al, 201431 Multicenter, prospective 
2001 - 2005 
FU: 5.2 – 10.0 (7.0) 
26 
CNS-PNET 
and PBL 
42% (11) 6 – 22.8 (15.6) 
Perreault et al, 2013 and 
20149,10 
Retrospective, 2 center  
2000 – 2011 
FU: 0.25 – 11.4 (3.7)  
25 
Supratentorial 
PNET only 
56% (14) 3 – 54 (11.5) 
High-grade glioma (HGG) and Diffuse intrinsic pons glioma (DIPG) 
Macy et al, 201735 Prospective  
2009 – 2012  
FU up to 3.7 
45 
DIPG n=25 
HGG n=20 
75% (34) at 1 year  n.a.  
Wolff et al, 201136 Prospective  
2002 - 2003 
30 
DIPG and 
HGG 
 
EFS at 1, 2 and 5 
years  
= 43, 20 and 13% 
n.a. 
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Abbreviations: CNS-PNET= central nervous system primitive neuroectodermal tumor; DIPG= diffuse intrinsic pons glioma; FU= follow-up; HGG= 
high grade glioma; IMRT= intensity-modulated radiation therapy; PBL= pineoblastoma; PRT= proton-beam radiation therapy; SHH= sonic 
hedgehog  
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TABLE 2 Summary of the most important findings from the eligible studies on secondary malignant neoplasm, intracerebral vascular malformation 
and white matter lesion 
Study/ Year Trial type 
Year of treatment 
FU, y, median 
Number of 
patients 
Primary 
tumor biology 
Number of SMN 
and biology 
Latency, y, median 
Secondary malignant neoplasm (SMN) 
Dufour et al, 201411 Single center 
2001 – 2010 
FU: 0.8 – 11.3 (4.4) 
24 MB  4.1% (1/24) 
- 1x HGG  
After 9.3  
Karremann et al, 201537 Multicenter, prospective 
1995 - 2007 
FU: 0 – 13.8 (1.0) 
1228 HGG and 
DIPG 
0.16% (2/1228)  
- 1x MGM 
- 1x PNET  
2.4 (PNET) and 10.2 (MGM) 
 
Massimino et al, 201138 Multicenter, prospective 
1994 – 2003 
FU: 1.2 – 15.0 (8.3) 
41 EPN  2.4% (1/41) 
- 1x HGG 
6.0  
Packer et al, 201339 
 
Multicenter 
1996 – 2000 
FU: 0.2 – 13.7 (9.7) 
379 MB  
 
1.8% (7/379) 
- 6x HGG 
- 1x LGG  
3.7 – 10.3 (6.5)  
Sabel et al, 20167 Multicenter, prospective 
2001 – 2006  
FU: (7.8) 
338 MB 
 
0.6% (2/338) 
- 1x DIPG 
- 1x HGG 
5.1 (DIPG) and 4.6 (HGG) 
Von Hoff et al, 200940 Multicenter, prospective  
1991 – 1997  
FU: (10.0)  
280 MB 
 
2.1% (6/280) 
- 3x HGG 
- 2x MGM 
- 1x DIPG 
n.a. 
Intracerebral vascular malformations (IVM) 
Study/ Year Trial type 
Year of treatment 
FU, y, median 
Number of 
patients 
Primary 
tumor biology 
Number of IVM  Latency, y, median 
Lew et al, 200641 Single center, retrospective  59 MB 31% (18/59) 1.1 – 16.1 (6.6) 
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1996 – to present 
FU: 1 – 25.3 (7.2) 
 
 
Leukoencephalopathy/ White matter lesions (WML)  
Study/ Year Trial type 
Year of treatment  
FU, y, median 
Number of 
patients 
Primary 
tumor biology 
Number of WML Latency, y, median 
Brinkman et al, 201246 Single center, prospective  
Year of treatment: n.a. 
FU: average 18yr  
20 MB 80% (16/20)  
- Grade: n.a.  
 
12 – 25 between treatment 
and evaluation  
Dietrich et al, 200144 Retrospective 
Year of treatment: n.a. 
FU: 0.5 – 15 (3.8) 
44 MB n=28 
EPN n=2 
PNET n=5 
PBL n=2 
Other n=7 
63.6% (28/44)  
- Grade I: n=13 
- Grade II: n=2 
- Grade III/IV: cystic  
   n=10, hemorrhagic  
   n=3 
n.a. 
Kellie et al, 200543 Multicenter, retrospective  
1990s 
FU: 4.0 – 10.5 (6.5) 
12 MB n=9 
PBL n=3 
100% (12/12) 
- Grade I n=8 
- Grade II n=4 
4 cases with serial MRI: 
grade II changes in the first 
year; progressive WML and 
lacunes after 5 and 6 years 
Rueckriegel et al, 
201045 
Prospective 
Year of treatment: n.a. 
FU: (3.8) 
17 MB  94% (16/17) 
- Grade I n=11 
- Grade II n=5 
n.a. 
 
Abbreviations: DIPG= diffuse intrinsic pons glioma; EPN= ependymoma; FU= follow-up; HGG= high-grade glioma; LGG= low-grade glioma; 
MB= medulloblastoma; MGM= meningioma; MRI= magnetic resonance imaging; PBL= pineoblastoma; PNET= primitive neuroectodermal tumor; 
WML= white matter lesion 
 
